

Yuan-Kai Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3996164/publications.pdf>

Version: 2024-02-01

135
papers

6,745
citations

159585

30
h-index

71685

76
g-index

155
all docs

155
docs citations

155
times ranked

8392
citing authors

#	ARTICLE	IF	CITATIONS
1	Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. <i>Haematologica</i> , 2022, 107, 1633-1642.	3.5	21
2	Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study. <i>Chinese Medical Journal</i> , 2022, 135, 433-440.	2.3	2
3	Medication therapy of high-dose methotrexate: An evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2456-2472.	2.4	9
4	Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1681-1691.	4.2	7
5	Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Cancer Biology and Medicine</i> , 2022, 19, 1-17.	3.0	7
6	Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 25.	17.1	12
7	Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data. <i>Future Oncology</i> , 2022, 18, 1679-1689.	2.4	9
8	Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional study. <i>Thoracic Cancer</i> , 2022, 13, 1684-1690.	1.9	3
9	Enhancement of the International prognostic index with β_2 -microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era. <i>BMC Cancer</i> , 2022, 22, .	2.6	4
10	Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 3071-3085.	4.2	5
11	Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. <i>Leukemia</i> , 2021, 35, 312-332.	7.2	151
12	A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2741-2746.	2.0	11
13	Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients. <i>Thoracic Cancer</i> , 2021, 12, 1943-1951.	1.9	26
14	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 678-689.	10.7	83
15	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small cell lung cancer: A multicenter, randomized, double-blind, phase III trial. <i>Cancer Communications</i> , 2021, 41, 889-903.	9.2	16
16	Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTERO303 trial. <i>Thoracic Cancer</i> , 2021, 12, 2345-2351.	1.9	5
17	Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study. <i>Chronic Diseases and Translational Medicine</i> , 2021, 7, 190-198.	1.2	0
18	Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy. <i>Journal of Translational Medicine</i> , 2021, 19, 399.	4.4	2

#	ARTICLE	IF	CITATIONS
19	The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era. <i>Leukemia Research</i> , 2021, 110, 106715.	0.8	6
20	Anti- μ 53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta-analysis. <i>Scandinavian Journal of Immunology</i> , 2020, 91, e12829.	2.7	21
21	Whole-genome sequencing of prostate cancer reveals novel mutation-driven processes and molecular subgroups. <i>Life Sciences</i> , 2020, 254, 117218.	4.3	14
22	Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, e204429.	7.1	22
23	Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients. <i>Cancer Management and Research</i> , 2020, Volume 12, 11515-11522.	1.9	8
24	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. <i>Lung Cancer</i> , 2020, 150, 240-246.	2.0	10
25	Validation of the IMPROVE bleeding risk score in Chinese medical patients during hospitalization: Findings from the dissolve-2 study. <i>The Lancet Regional Health - Western Pacific</i> , 2020, 4, 100054.	2.9	3
26	Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2413-2424.	4.2	21
27	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). <i>Journal of Hematology and Oncology</i> , 2020, 13, 143.	17.0	226
28	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1857-1870.	1.1	19
29	Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors. <i>JAMA Network Open</i> , 2020, 3, e2013201.	5.9	54
30	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. <i>International Journal of Cancer</i> , 2020, 147, 2611-2620.	5.1	12
31	Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients. <i>Theranostics</i> , 2020, 10, 6399-6410.	10.0	26
32	Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases. <i>Oncology Research</i> , 2020, 28, 127-133.	1.5	5
33	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 6.	17.0	13
34	Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. <i>European Journal of Cancer</i> , 2020, 130, 182-192.	2.8	46
35	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. <i>Cancer Biology and Medicine</i> , 2020, 17, 896-909.	3.0	35
36	Genomutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 6812-6821.	3.6	12

#	ARTICLE	IF	CITATIONS
37	Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy. <i>Journal of Translational Medicine</i> , 2019, 17, 339.	4.4	8
38	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER0303. <i>Thoracic Cancer</i> , 2019, 10, 551-556.	1.9	42
39	CMAB009 plus irinotecan versus irinotecan only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. <i>Cancer Communications</i> , 2019, 39, 1-13.	9.2	6
40	Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. <i>BMJ Open</i> , 2019, 9, e028589.	1.9	1
41	Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study. <i>Targeted Oncology</i> , 2019, 14, 149-158.	3.6	14
42	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	1.1	260
43	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579.	2.5	31
44	Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2019, 24, e1251-e1261.	3.7	29
45	Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2019, 12, 9.	17.0	22
46	Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e12-e19.	4.6	176
47	VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients. <i>Chest</i> , 2019, 155, 114-122.	0.8	51
48	Clinicopathologic characteristics and outcome of patients with different EGFR mutations. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 166-171.	1.1	7
49	Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study. <i>Blood</i> , 2019, 134, 1568-1568.	1.4	11
50	Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 152-161.	2.2	66
51	Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases. <i>Current Cancer Drug Targets</i> , 2019, 19, 666-673.	1.6	11
52	A phase II trial with the combination of plinabulin (plin) pegfilgrastim (peg): Evaluation of the reversal of peg's immune-suppressive potential by the addition of plin to peg. <i>Journal of Clinical Oncology</i> , 2019, 37, 4-4.	1.6	0
53	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	6.4	192
54	Current status and progress of lymphoma management in China. <i>International Journal of Hematology</i> , 2018, 107, 405-412.	1.6	26

#	ARTICLE	IF	CITATIONS
55	Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. <i>American Journal of Hematology</i> , 2018, 93, 607-614.	4.1	75
56	Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure. <i>Cancer Science</i> , 2018, 109, 3943-3952.	3.9	26
57	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 32-37.	2.0	32
58	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 681-690.	10.7	166
59	Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. <i>Cancer Communications</i> , 2018, 38, 1-9.	9.2	7
60	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	1.1	146
61	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1569.	7.1	388
62	Effect of JS001, a monoclonal antibody targeting programmed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 11572-11572.	1.6	5
63	Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study). <i>Journal of Clinical Oncology</i> , 2018, 36, 7536-7536.	1.6	3
64	Subgroup analysis of elderly patients (pts) in ALTER0303: Anlotinib hydrochloride as 3 rd -line and further line treatment in refractory advanced NSCLC pts from a randomized, double-blind, placebo-controlled phase III ALTER0303 trial. <i>Journal of Clinical Oncology</i> , 2018, 36, e21181-e21181.	1.6	3
65	Comprehensive gene copy number alterations profiling predict efficacy of adjuvant chemotherapy in resected stage II-IIIa lung adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, e24278-e24278.	1.6	9
66	Rh-endostatin combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in NSCLC: A retrospective comparison with standard chemotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, e21198-e21198.	1.6	0
67	Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase II results from a head-to-head comparison with Pegfilgrastim (Peg). <i>Journal of Clinical Oncology</i> , 2018, 36, 2528-2528.	1.6	0
68	BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study. <i>Journal of Clinical Oncology</i> , 2018, 36, e21108-e21108.	1.6	0
69	The genome patterns of prostate cancer in national cancer center in China. <i>Journal of Clinical Oncology</i> , 2018, 36, e17090-e17090.	1.6	0
70	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 9077-9077.	1.6	1
71	Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 379-384.	1.1	0
72	P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S886-S887.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69.	17.0	155
74	Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2017, 96, 1477-1483.	1.8	20
75	Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma not otherwise specified. <i>Annals of Hematology</i> , 2017, 96, 245-251.	1.8	18
76	Plasma Lipidomic Analysis to Identify Novel Biomarkers for Hepatocellular Carcinoma. <i>Journal of Analysis and Testing</i> , 2017, 1, 223-232.	5.1	4
77	Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 7.	17.0	17
78	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000219.	4.5	87
79	Third-line treatment: A randomized, double-blind, placebo-controlled phase III ALTER-0303 study Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC. <i>Journal of Clinical Oncology</i> , 2017, 35, 9053-9053.	1.6	10
80	Apatinib plus icotinib in treating advanced non-small-cell lung cancer after icotinib treatment failure. <i>Journal of Clinical Oncology</i> , 2017, 35, e20528-e20528.	1.6	0
81	Whole exome sequencing identifies novel prognostic biomarker in colon cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, e15098-e15098.	1.6	0
82	An updated analysis of ICOGEN to demonstrate utility of a blood-based proteomic test to predict outcomes in EGFR TKI treated patients. <i>Journal of Clinical Oncology</i> , 2017, 35, e20655-e20655.	1.6	0
83	Dynamic process of circulating tumour DNA (ctDNA) profiling as a predictor of efficacy of pemetrexed combined platinum chemotherapy in advanced lung adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, e23048-e23048.	1.6	0
84	Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, 9, 2911.	2.0	18
85	Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era. <i>Chinese Medical Journal</i> , 2016, 129, 2780-2785.	2.3	3
86	Prognostic impact of mutation profiling in patients with stage II and III colon cancer. <i>Scientific Reports</i> , 2016, 6, 24310.	3.3	30
87	Development and validation of a UHPLC-MS/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1025, 119-125.	2.3	0
88	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 577-589.	10.7	950
89	Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. <i>Hematology</i> , 2016, 21, 536-541.	1.5	13
90	Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases. <i>Thoracic Cancer</i> , 2016, 7, 437-441.	1.9	4

#	ARTICLE	IF	CITATIONS
91	A prognostic model for platinumâ€doublet as secondâ€line chemotherapy in advanced nonâ€smallâ€cell lung cancer patients. <i>Cancer Medicine</i> , 2016, 5, 1116-1124.	2.8	8
92	PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7506-7506.	1.6	16
93	Phase 3 study of first-line crizotinib vs pemetrexedâ€cisplatin/carboplatin (PCC) in East Asian patients (pts) with <i>ALK</i>+ advanced non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9058-9058.	1.6	7
94	Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. <i>Oncotarget</i> , 2016, 7, 72219-72228.	1.8	8
95	Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). <i>Cancer</i> , 2015, 121, 3165-3181.	4.1	47
96	Ventana immunohistochemistry ALK (D5F3) detection of ALK expression in pleural effusion samples of lung adenocarcinoma. <i>Personalized Medicine</i> , 2015, 12, 349-357.	1.5	1
97	Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkinâ€™s lymphoma. <i>Chinese Journal of Cancer</i> , 2015, 34, 522-30.	4.9	7
98	Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas. <i>Chinese Medical Journal</i> , 2015, 128, 2498-2504.	2.3	4
99	miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer. <i>Oncology Reports</i> , 2015, 34, 3088-3096.	2.6	47
100	Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 569-575.	1.3	7
101	Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 877-887.	3.1	58
102	Chinese perspective of the role of primary care in cancer control. <i>Lancet Oncology</i> , The, 2015, 16, 1227-1228.	10.7	2
103	An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8039-8039.	1.6	2
104	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <i>PLoS ONE</i> , 2015, 10, e0142500.	2.5	14
105	Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology â€ Mainland China Subset Analysis of the PIONEER study. <i>PLoS ONE</i> , 2015, 10, e0143515.	2.5	143
106	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <i>Journal of Thoracic Disease</i> , 2015, 7, E468-72.	1.4	6
107	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <i>Annals of Translational Medicine</i> , 2015, 3, 260.	1.7	9
108	Comprehensive analysis of driver mutations in Chinese squamous cell lung carcinomas by targeted next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7544-7544.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19048-e19048.	1.6	0
110	Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 239-46.	2.2	8
111	Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 516-23.	2.2	2
112	The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy. <i>PLoS ONE</i> , 2014, 9, e84501.	2.5	27
113	Phase III trial of paclitaxel+carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 149-154.	1.9	4
114	Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment Responses. <i>Clinical Cancer Research</i> , 2014, 20, 6016-6022.	7.0	80
115	Analysis of clinicopathological features of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 255-260.	1.9	3
116	A MicroRNA Signature Predicts Survival in Early Stage Small-Cell Lung Cancer Treated with Surgery and Adjuvant Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e91388.	2.5	39
117	Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study. <i>Molecular and Clinical Oncology</i> , 2014, 2, 87-92.	1.0	11
118	A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). <i>Journal of Thoracic Oncology</i> , 2014, 9, 154-162.	1.1	1,131
119	The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 1291-1298.	0.8	13
120	The global implications of diabetes and cancer. <i>Lancet, The</i> , 2014, 383, 1947-1948.	13.7	327
121	In Response. <i>Journal of Thoracic Oncology</i> , 2014, 9, e58-e59.	1.1	0
122	Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6061-6061.	1.6	6
123	Antitumor Effects of a Novel Chromosome Region Maintenance 1 (CRM1) Inhibitor on Non-Small Cell Lung Cancer Cells In Vitro and in Mouse Tumor Xenografts. <i>PLoS ONE</i> , 2014, 9, e89848.	2.5	32
124	Autologous peripheral blood stem cell mobilization following high-dose CHOP chemotherapy combined with rituximab in patients with NHL.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18003-e18003.	1.6	0
125	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. <i>Lancet Oncology, The</i> , 2013, 14, 953-961.	10.7	389
126	Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens. <i>Anti-Cancer Drugs</i> , 2013, 24, 641-647.	1.4	20

#	ARTICLE	IF	CITATIONS
127	Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study. <i>Thoracic Cancer</i> , 2013, 4, 109-116.	1.9	7
128	Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7559-7559.	1.6	4
129	Visual effects in anaplastic lymphoma kinase (<i>ALK</i>)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7596-7596.	1.6	6
130	Phase I/II trial of sorafenib combined with FOLFOX4 in untreated patients with advanced gastric adenocarcinoma: Phase I results.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14606-e14606.	1.6	0
131	Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma. <i>International Journal of Hematology</i> , 2009, 89, 106-112.	1.6	1
132	Reply to "A promoter polymorphism in the CASP8 gene is not associated with cancer risk". <i>Nature Genetics</i> , 2008, 40, 260-261.	21.4	14
133	Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study. <i>Chemotherapy</i> , 2007, 53, 44-50.	1.6	39
134	In vitro study on cryopreservation of peripheral blood stem cells with uncontrolled freezer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2002, 14, 235-239.	2.2	0
135	High dose chemoradiotherapy with autologous hematopoietic stem cell transplantation in the treatment of advanced Hodgkin's lymphoma: A report of 11 cases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2002, 14, 254-258.	2.2	0